Glaukos Corporation (GKOS) Stock Price & How to Invest

Last updated November 2026

Short answer

Glaukos (GKOS) is a US-listed ophthalmic medical technology and pharmaceutical company built around glaucoma and corneal-disease treatments, and it trades as a high-growth medtech story that has only just turned profitable where the pace of its newer implant and drug launches drives the case. You buy GKOS through any standard brokerage as a bet that products like iDose TR and Epioxa scale faster than legacy-business and reimbursement headwinds bite. As of November 20, 2026 the stock closed near $236.60, up about 114% year to date and about 149% over the past year, for a market value of roughly $14 billion, after a third quarter in which sales rose about 58% and the company posted a small net profit.

GKOS stock price

As of 2026-11-20, Glaukos Corporation (GKOS) last closed at $237.31, up 138.2% over the past year. Over the past 52 weeks it has traded between $97.02 and $247.16.

GKOS last close
$237.31
1 day
-0.33%
1 month
+34.19%
1 year
+138.22%
52-week range
$97.02 to $247.16
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Glaukos Corporation's investor relations page. Walnut is informational, not investment advice.

GKOS key stats

At $237.31 on November 20, 2026, Glaukos Corporation (GKOS) has a market cap of $14.0B.

Market cap
$14.0B
P/E (forward)
169.5
Price to book
19.6
Beta
0.68

Market cap, P/E and yield are measured at the $237.31 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Glaukos Corporation (GKOS)?

The last two weeks for Glaukos Corporation, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • GKOS closed at $237.31 on November 20, 2026, down 3.4% over the past five trading days (from $245.72).
  • On November 16, 2026, BTIG raised its target to $252.00 from $234.00 (Buy).

Glaukos Corporation filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Glaukos Corporation (GKOS) latest quarter

Glaukos reported revenue of $211 million for Q3 2026, up 58% from a year earlier (Glaukos, Oct 28, 2026).

Revenue
$211 million
up 58% from a year earlier
Diluted EPS (GAAP)
$0.03
n/a
U.S. Glaucoma
$119 million
up 47% from a year earlier

Source: Glaukos Q3 2026 results, Oct 28, 2026. Full earnings breakdown

What does Glaukos Corporation (GKOS) do?

Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. In October 2026 it added a retinal program by licensing RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The company sells through eye surgeons and clinics in the US and internationally. Growth has been accelerating: Q1 2026 net sales were roughly $150.6 million, up about 41% year over year (iDose TR contributed around $54 million), Q2 2026 net sales reached about $185.6 million, up roughly 50%, and Q3 2026 net sales reached about $211.0 million, up roughly 58%, taking trailing twelve-month revenue to about $690 million.

The investment picture is a growth-versus-valuation tradeoff that has shifted toward profitability. Revenue is compounding quickly, with analysts expecting about $781 million for full-year 2026 and about $1 billion in 2027. After net losses of about $19.8 million in Q1 and $18.4 million in Q2 2026, Glaukos earned a small net profit of about $2.0 million in Q3, and adjusted EPS of $0.47 beat the roughly $0.09 loss analysts expected. The trailing net loss of about $170 million is still inflated by a roughly $134 million loss in Q4 2025. It held about $337 million in cash against roughly $105 million of debt at the end of September, produced about $53 million of free cash flow over the trailing year, and the stock trades near 20 times trailing sales and about 169 times forward earnings, so the valuation leans on continued rapid adoption of iDose TR and Epioxa. Walnut is not an investment adviser; this is descriptive context, not a recommendation.

What's driving Glaukos Corporation (GKOS)?

1. iDose TR ramp

The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. Its adoption reflects a shift toward procedural, drug-eluting glaucoma care rather than daily eye drops. Continued reimbursement clarity and a growing base of peer-reviewed clinical evidence support the ramp. In October 2026 Glaukos reported that a Phase 4 randomized trial of iDose TR combined with cataract surgery met its primary efficacy endpoint, adding to the evidence base surgeons look at.

2. Corneal health and Epioxa

The corneal-health segment (Photrexa and the newer Epioxa incision-free cross-linking therapy for keratoconus) is a second growth engine. A CMS permanent J-code for Epioxa helps de-risk near-term reimbursement and access as the launch scales. This diversifies Glaukos beyond glaucoma devices into rare corneal disease. In October 2026 the company also released three-year Phase 3 extension data showing durable efficacy and a favorable safety profile for Epioxa.

3. International expansion

International glaucoma procedures are growing, aided by the European commercial launch of iStent Infinite following EU MDR certification. Overseas markets broaden the addressable base beyond the US. This gives Glaukos additional runway even as domestic MIGS competition intensifies.

4. Path toward profitability

Rapid top-line growth combined with about $337 million in cash (against roughly $105 million of debt) gives Glaukos room to invest through its launches. Gross margin is about 81%, and the loss per share narrowed from $0.18 in Q1 2026 to $0.14 in Q2 before adjusted EPS turned positive at $0.47 in Q3, when GAAP net income was about $2.0 million. Analysts on average expect about $0.47 of EPS in Q4 2026 and about $1.40 in 2027, so the open question has moved from whether Glaukos can turn a profit to how quickly operating leverage builds, with operating margin still about -9% on a trailing basis.

What are the risks to Glaukos Corporation (GKOS)?

Glaukos has only one profitable quarter behind it and trades at about 20 times trailing sales and about 169 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter. The shares have swung widely, from a 52-week low near $94 to a high near $255, and rose about 32% in the month to November 20, 2026, so the price now sits close to the average analyst target of about $244. The new RO-104 retinal license adds early-stage development risk.

What is the Glaukos Corporation (GKOS) forecast?

13 analysts publish price targets on GKOS, averaging $243.85 as of November 2026, or +2.8% against the $237.31 share price on November 20, 2026. The published targets run from $225.00 to $270.00, a narrow spread, and the ratings split 12 buy, 1 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GKOS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is GKOS a buy or a sell?

We give no verdict on Glaukos Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. iDose TR ramp. The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. The most optimistic published target, $270.00, assumes this works close to its best case.

The case against. Glaukos has only one profitable quarter behind it and trades at about 20 times trailing sales and about 169 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. The most pessimistic target, $225.00, is roughly what GKOS is worth if this bites instead.

Read the full bull and bear case on GKOS, including what would have to change to break either one. Walnut is not an investment adviser.

Has Glaukos Corporation (GKOS) split its stock?

No. Glaukos Corporation (GKOS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Glaukos Corporation (GKOS) valued?

Market cap, P/E and dividend yield at today's price are in the GKOS key stats above. The business figures below come from Glaukos Corporation's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$690M
  • Q3 2026 net sales: ~$211.0M (up ~58% YoY)
  • 2026 revenue (analyst consensus): ~$781M; 2027 ~$1.0B
  • Gross margin: ~81%
  • Net income: ~-$170M TTM; Q3 2026 ~+$2.0M; Q3 adjusted EPS $0.47 vs -$0.09 est.
  • Cash / debt: ~$337M / ~$105M

As of November 2026: Glaukos combines roughly 58% revenue growth with its first small quarterly profit, so it screens as a high-multiple growth medtech, not a value name, with a negative trailing P/E and a forward P/E near 169. After a roughly 149% one-year gain the stock sits just below the average analyst target of about $244. The next report, for the fourth quarter, carries consensus of about $233 million of revenue and $0.47 of EPS.

Which ETFs hold Glaukos Corporation (GKOS)?

If you want GKOS exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in GKOSExpense ratio
IJRiShares Core S&P Small-Cap ETF0.80%0.06%
IWMiShares Russell 2000 ETF0.46%0.19%
SCHASchwab U.S. Small-Cap ETF0.34%0.03%
VTWOVanguard Russell 2000 Index Fund ETF Shares0.45%0.06%
SPSMState Street SPDR Portfolio S&P 600 Small Cap ETF0.80%0.03%
IWOiShares Russell 2000 Growth ETF0.92%0.24%
IJTiShares S&P Small-Cap 600 Growth ETF1.2%0.18%
VIOOVanguard S&P Small-Cap 600 Index Fund ETF Shares0.8%0.07%
FESMFidelity Enhanced Small Cap Core ETF1.0%0.28%
SLYGState Street SPDR S&P 600 Small Cap Growth ETF1.2%0.15%

Who competes with Glaukos Corporation (GKOS)?

Glaucoma surgical devices (MIGS)

Alcon (Hydrus Microstent), Sight Sciences (Omni), AbbVie, and Johnson & Johnson (Xen Gel Stent), plus New World Medical and Iantrek, compete directly with Glaukos iStent implants for micro-invasive glaucoma surgery share.

Glaucoma drug delivery

In sustained-release glaucoma therapy, iDose TR competes with traditional daily eye drops and with other procedural drug-delivery approaches from large ophthalmic pharma players such as AbbVie and Alcon, where iDose TR is currently positioned ahead of most peers.

Corneal and broader ophthalmology

In corneal health, Photrexa and Epioxa operate in a narrower keratoconus and cross-linking niche, while the wider ophthalmic market includes Santen, Carl Zeiss, Bausch + Lomb, and other specialty eye-care companies expanding their device and therapeutic lines.

What stocks are similar to Glaukos Corporation (GKOS)?

Other names that sit close to GKOS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Glaukos Corporation (GKOS)

There are three common ways to get GKOS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (IJR, IWM, SCHA), which spreads the position across many companies. Or build it into a focused thematic portfolio, so GKOS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GKOS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Glaukos Corporation (GKOS)

GKOS is a fast-growing, cash-funded eye-care medtech whose story rides on new-product adoption outpacing competition and reimbursement risk as it moves into profitability. Revenue growth accelerated again to about 58% in the third quarter of 2026, adjusted EPS of $0.47 swung far above the expected $0.09 loss, and the stock has gained about 32% in the past month alone and more than doubled in 2026, so the valuation now assumes that growth continues.

More on Glaukos Corporation (GKOS)

Whether GKOS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GKOS a buy or a sell?, and where the stock could go from here in the GKOS stock forecast.

For income investors, whether GKOS pays a dividend and how the payout looks is covered in does GKOS pay a dividend? And to weigh GKOS against a peer, read the full side-by-side comparisons: GKOS vs ALC and GKOS vs ABBV.

Wondering how GKOS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Glaukos Corporation

Ask Walnut's AI anything about GKOS and see how it fits what you own.

FAQ

What does Glaukos (GKOS) do?

+

Glaukos is an ophthalmic medical technology and pharmaceutical company. It develops and sells treatments for glaucoma, corneal disorders, and retinal disease, including the iStent surgical implants, the iDose TR drug-delivery implant, and corneal therapies Photrexa and Epioxa.

Is Glaukos profitable?

+

Only just. Glaukos reported net losses of about $19.8 million in Q1 2026 and $18.4 million in Q2, then a small net profit of about $2.0 million in Q3 2026, with adjusted EPS of $0.47 against the roughly $0.09 loss analysts expected. Over the last twelve months it still shows a net loss of about $170 million, mostly from a roughly $134 million loss in Q4 2025, as it invests heavily in commercial launches and R&D. Analysts on average expect about $0.47 of EPS in Q4 2026 (as of November 2026).

How fast is Glaukos growing?

+

Very fast for a medtech company. Q3 2026 net sales rose about 58% year over year to roughly $211.0 million, after about 50% growth in Q2 and about 41% in Q1. Trailing twelve-month revenue is about $690 million, and analysts expect about $781 million for full-year 2026 and about $1 billion for 2027 (as of November 2026).

What is iDose TR and why does it matter?

+

iDose TR is a sustained-release implant that delivers glaucoma medication inside the eye over an extended period, reducing reliance on daily eye drops. It is Glaukos's largest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma segment. In October 2026 a Phase 4 randomized trial of iDose TR with cataract surgery met its primary efficacy endpoint.

Who competes with Glaukos?

+

In glaucoma surgical devices, competitors include Alcon, Sight Sciences, AbbVie, and Johnson & Johnson, plus New World Medical and Iantrek. In broader ophthalmology, players such as Santen, Carl Zeiss, and Bausch + Lomb are also present across devices and therapeutics.

What are the main risks for GKOS?

+

Key risks include a high valuation (about 20 times sales and 169 times forward earnings) with only one profitable quarter so far, reimbursement complexity (including Medicaid rebate impacts on Photrexa), intense competition in glaucoma devices, flattish trends in the legacy iStent business outside iDose, and execution risk on scaling newer launches like Epioxa.

Does Glaukos pay a dividend?

+

No. Glaukos does not pay a dividend. As a growth-stage medical technology company reinvesting in launches and R&D, it directs cash toward expansion, not shareholder payouts, so any return would come from share-price appreciation, not income (as of November 2026).

How can I invest in GKOS?

+

Glaukos trades on the NYSE under the ticker GKOS and can be bought through any standard US brokerage account. Walnut is not an investment adviser, so consider your own goals and risk tolerance, and note that GKOS is a volatile growth stock that has only recently reached a quarterly profit.

How did Glaukos do in its latest quarter?

+

In Q3 2026 Glaukos reported net sales of about $211.0 million, up roughly 58% from a year earlier and well above the roughly $168 million analysts had expected before the report. Adjusted EPS was $0.47, against an expected loss of about $0.09, and GAAP net income was about $2.0 million, a turn from losses of about $18.4 million in Q2. For Q4 2026, consensus is near $233 million of revenue and $0.47 of EPS.

How has GKOS stock performed in 2026?

+

As of November 20, 2026, Glaukos closed at about $236.60, up about 114% year to date and about 149% over the past year, with a gain of about 32% in the past month after its third-quarter report. Its 52-week range runs from roughly $94 to $255. The 13 analysts in Yahoo's consensus had an average target near $244. Past performance says nothing certain about future returns.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Glaukos Corporation's investor relations page or your broker before making investment decisions.